Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsRagnarsson, G B
Mikaelsdottir, E K
Jonasson, J G
Ogmundsdóttir, H M
MetadataShow full item record
CitationBr. J. Cancer. 2000, 83(12):1715-21
AbstractFas ligand (FasL) is expressed on some cancers and may play a role in the immune evasion of the tumour. We used immuno-histochemistry to study the expression of Fas and FasL in tissue samples from breast cancer patients, as well as normal breast tissue. Our results show that Fas and FasL are co-expressed both in normal tissue and in breast tumours. Fas and FasL mRNA were expressed in fresh normal and malignant breast tissue, as well as cultured breast epithelium and breast cancer cell lines. Flow cytometry analysis of live cells failed to detect FasL on the surface of normal or malignant breast cells; however, both stained positive for FasL after permeabilization. Fas was detected on the surface of normal breast cells and T47D and MCF-10A cell lines but only intracellularly in other breast cell lines tested. Neither normal breast epithelium nor breast cell lines induced Fas-dependent apoptosis in Jurkat cells. Finally, 20 tumour samples were stained for apoptosis. Few apoptotic cells were detected and there was no increase in apoptotic cells on the borders between tumour cells and lymphocytes. We conclude that FasL is expressed intracellularly in both normal and malignant breast epithelium and unlikely to be important for the immune evasion of breast tumours.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
- Authors: Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A
- Issue date: 2000 Jan
- Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
- Authors: Lee TB, Min YD, Lim SC, Kim KJ, Jeon HJ, Choi SM, Choi CH
- Issue date: 2002 Jan
- Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
- Authors: Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E
- Issue date: 2003 Oct
- Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
- Authors: Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, Kabelitz D, Friese K
- Issue date: 2000 Mar
- Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
- Authors: Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H
- Issue date: 1998 Apr 15